Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Cell Culture-Derived vs Egg-Derived Influenza Vaccine in Adults and Elderly
NCT00492063Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2004
- Primary completion
- Dec 2004
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated) in influenza (2 arms), sponsored by Novartis. Primary endpoints: Percentage of Subjects Who Achieved HI Titer >= 40 at Day 22, Percentage of Subjects Who Achieved Seroconversion or Significant Increase in HI Titer at Day 22 and 1 more. Started Sep 2004; status: completed.
02
Drugs
Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00492063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492063.